{
  "source": "PA-Notification-Somavert.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1193-9\nProgram Prior Authorization/Notification\nMedication Somavert® (pegvisomant)\nP&T Approval Date 7/2016, 7/2017, 7/2018, 7/2019, 7/2020, 7/2021, 7/2022, 7/2023, 7/2024\nEffective Date 10/1/2024\n1. Background:\nSomavert (pegvisomant) is a growth hormone receptor antagonist indicated for the treatment of\nacromegaly in patients who have had an inadequate response to surgery or radiation therapy, or\nfor whom these therapies are not appropriate. The goal of treatment is to normalize serum insulin-\nlike growth factor-I (IGF-I) levels.1\n2. Coverage Criteriaa:\nA. Acromegaly\n1. Initial Authorization\na. Somavert will be approved based on both of the following criteria:\n(1) Diagnosis of acromegaly\n-AND-\n(2) One of the following:\n(a) Inadequate response to one of the following:\ni. Surgery\nii. Radiation therapy\n-OR-\n(b) Not a candidate for either of the following:\ni. Surgery\nii. Radiation therapy\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Somavert will be approved based on the following criterion:\n(1) Documentation of positive clinical response to Somavert therapy\nAuthorization will be issued for 12 months.\n© 2024 UnitedHealthcare Services, Inc.\n1\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits and/or Step Therapy may be in place.\n4. References:\n1. Somavert [package insert]. New York, NY: Pfizer Inc.; July 2023.\nProgram Prior Authorization/Notification – Somavert® (pegvisomant)\nChange Control\n7/20",
    " Step Therapy may be in place.\n4. References:\n1. Somavert [package insert]. New York, NY: Pfizer Inc.; July 2023.\nProgram Prior Authorization/Notification – Somavert® (pegvisomant)\nChange Control\n7/2016 New program\n7/2017 Annual review. No changes to the program.\n7/2018 Annual review. No changes to the program.\n7/2019 Annual review. No changes to the program.\n7/2020 Annual review. No changes to coverage criteria.\n7/2021 Annual review. No changes to coverage criteria.\n7/2022 Annual review. Added state mandate with no other changes to coverage\ncriteria. Reference updated.\n7/2023 Annual review. No changes to coverage criteria.\n7/2024 Annual review with no changes to coverage criteria. Updated\nreference.\n© 2024 UnitedHealthcare Services, Inc.\n2"
  ]
}